Evaluation of a Polyherbal Formulation on the Management of Migraine Headaches due to Functional Dyspepsia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
Table 1
Demographic characteristics of the participants in the present study in an overview.
Variables
Group 1
Group 2
Group 3
Total
Gender; N (%)
Female
18 (78.2%)
19 (82.6%)
15 (68.1%)
52 (76.4%)
Male
5 (21.8%)
4 (17.4%)
7 (31.9%)
16 (23.6%)
Marital status; N (%)
Single
6 (26.1%)
7 (30.4%)
3 (13.6%)
16 (23.5%)
Married
17 (73.9%)
16 (69.6%)
19 (86.4%)
52 (72.5%)
Type of migraine; N (%)
Without Aura
18 (78.2%)
17 (73.9%)
18 (78.2%)
53 (77.9%)
With Aura
6 (21.8%)
5 (26.1%)
4 (21.8%)
15 (12.1%)
Age (year); (Mean ± SD)
Male/Female
35 ± 10.6
37 ± 7.7
43 ± 13.3
38.3 ± 10.32
Weight (Kg); (Mean ± SD)
Male/Female
70 ± 18.8
69 ± 18.9
74 ± 17
71 ± 18.23
Education; N (%)
Under Diploma
11 (47.8%)
11 (47.8%)
8 (36.4%)
30 (44.2%)
University/College
12 (52.2%)
12 (52.2%)
14 (63.6%)
38 (55.8%)
Occupation; N (%)
Housewife
5 (21.7%)
7 (30.4%)
5 (22.7%)
17 (25%)
Employee
17 (73.9%)
16 (69.5%)
16 (72.7%)
49 (72%)
Unemployed
1 (4.3%)
0 (0%)
1 (4.5%)
2 (2.9%)
Family history of migraine
Male/Female
15 (65.2)
20 (87%)
17 (77.3%)
52 (76.4%)
Group 1: the polyherbal formulation capsule 1500 mg (two capsules of 750 mg) three times a day, + Depakine® tablet 200 mg twice a day + Amitriptyline tablet 10 mg once a day; Group 2: Depakine® tablet 200 Mg twice a day + Amitriptyline 10 mg once a day + the polyherbal formulation placebo capsule three times a day; Group 3: the polyherbal formulation capsule 1500 mg (two capsules of 750 mg) three times a day + Depakine® placebo tablet twice a day.
